regeneron.com - Likuiditas cepet REGN

Regeneron Pharmaceuticals (REGN) generates revenue from innovative biologics for the treatment of asthma and oncology, although biosimilar pressure is forcing the implementation of flexible discounts. The critical coverage metric 2.74 is recorded as a baseline value, demonstrating the liquidity level. However, a high dependence on a narrow drug portfolio amid fierce competition creates significant financial risks for the business.

This indicator excludes illiquid inventories by comparing cash and accounts receivable against short-term liabilities. The metric assesses the company's ability to instantly settle debts without liquidating warehouse stock. For Regeneron Pharmaceuticals (REGN), whose stability is supported by diversified biotechnology drug logistics, the current value of 2.74 confirms high solvency. Analyzing the net cash and receivables coverage ratio allows for the determination of the business's protection against sudden credit shocks.